PASITHEA THERAPEUTICS CORP. Cost of Revenue
PASITHEA THERAPEUTICS CORP. (KTTA) reported Cost of Revenue of $113.19 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2023-05-12
- PASITHEA THERAPEUTICS CORP. cost of goods and services sold for the quarter ending 2022-12-31 was -$1.31K.
- PASITHEA THERAPEUTICS CORP. cost of goods and services sold for the quarter ending 2022-09-30 was $86.47K.
- PASITHEA THERAPEUTICS CORP. cost of goods and services sold for the quarter ending 2022-06-30 was $15.10K.
- PASITHEA THERAPEUTICS CORP. cost of goods and services sold for the quarter ending 2022-03-31 was $12.94K.
- PASITHEA THERAPEUTICS CORP. cost of goods and services sold for fiscal 2022 was $113.19K, a 555.25% increase from fiscal 2021.
- PASITHEA THERAPEUTICS CORP. cost of goods and services sold for fiscal 2021 was $17.27K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$1.31K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $85.16K derived: sum of 2 quarters · filed 2023-03-30 | $100.26K derived: sum of 3 quarters · filed 2023-03-30 | $113.19K 10-K · filed 2023-03-30 |
| 2022-09-30 | $86.47K 10-Q · filed 2022-11-14 | $101.57K derived: sum of 2 quarters · filed 2022-11-14 | $114.50K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $15.10K 10-Q · filed 2022-08-15 | $28.04K 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $12.94K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $17.27K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |